Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Explore the various credit card rewards available and find out which ones truly offer value. Make informed choices for maximizing your benefits.
22,049 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
BuildersUpdate launched a pay-on-performance marketing model, charging a $750 fee per home only when a sale closes, a...
Energy leaders convene amid a tightening mix of growth and risk. AI-driven demand and geopolitical tensions push pric...
Palantir delivered an 85% year-over-year revenue surge in Q1 2026 and lifted full-year targets, but the shares are do...
Y Combinator will conduct crypto-focused startup interviews in New York for the first time, highlighting NYC's growin...
Bitcoin surged to a three-month high, topping the $82,000 mark amid fresh geopolitical chatter and improving market s...
IonQ is moving from early-stage hardware to recurring cloud access and software tools. This article breaks down what ...
Gen Z is saving record rates driven by auto-enrollment and digital tools, yet Beth Kobliner warns a single habit coul...
Uber’s first-quarter results sparked a rare split on Wall Street: Goldman Sachs trims the stock target, while Piper S...
Buffett’s moves often spark debates about dividend stocks. This article digs into the idea behind 'warren buffett own...
Rivian stock may get a lift not just from its R2 ramp but from a larger tech ecosystem catalyst: the potential SpaceX...
Coinbase missed earnings and then endured a multi-hour outage tied to an AWS failure, shaking investors. bulls argue ...